Predictive Oncology Inc. (NASDAQ: POAI) Uses Smart Tumor Profiling Platform with AI to Bring Value to Pharmaceutical, Biotech Industries

September 19, 2019 11:06:20
  • POAI’s artificial intelligence (AI)-driven tumor profiling platform brings precision medicine tools to clinicians and researchers to improve cancer outcomes
  • The company holds a critical strategic advantage over mammoth competitors, attracting investor attention
  • POAI is committed to providing sophisticated tools to help select current therapies more precisely and develop new targeted therapies

Predictive Oncology Inc. (NASDAQ: POAI) is working with the pharmaceutical and biotech industries to offer an AI-driven tumor profiling platform that clinicians and researchers can use to improve outcomes for cancer patients of today and tomorrow. POAI has built a distinctly valuable asset in its existing base of drug-response outcome evidence; this data has the potential to revolutionize the way cancer is treated (

Though seeming like David in the face of Goliath-sized competition, POAI holds a critical strategic advantage over such mammoth companies as Foundation Medicine and Tempus; while these competitors must wait at least five years to find out if the patient survived treatment before they can show value from their investments in gathering data, POAI’s dataset already contains large amounts of data going back more than 10 years, allowing it to build predictive models much more quickly and robustly. By simply analyzing the tumor it has already banked, Predictive Oncology can combine this with the drug response data it already has, delivering valuable, actionable insights to clinicians and researchers in months rather than years.

POAI’s technology combines its database of evidence documenting actual drug responses of cancer patients’ tumors with artificial intelligence (AI) to create an invaluable predictive tool for clinicians and researchers. Predictive Oncology’s data offers a valuable customizable assessment method that can be used by oncologists to determine the best drug for fighting a specific patient’s cancer. This disruptive technology is the first of its kind and is also meeting a critical need in the pharmaceutical, diagnostic and biotech industries to speed up the search for new precision therapies by providing tools to better predict how new drugs work on different cancers (

POAI’s wholly owned subsidiaries – Helomics and TumorGenesis – are working together to bring these important precision medicine tools to physicians. “The TumorGenesis platform and its methodology for tagging a tumor’s diverse cancer cell population is highly complementary to our Helomics discovery service business, which utilizes AI-driven tumor genetic and drug response profiling,” POAI CEO Dr. Carl Schwartz stated in a news release ( “Our vision is to tag every patient’s complex tumor cell populations first with biomarkers, creating a unique ‘fingerprint’ of that tumor to deliver a personalized medicine approach to cancer treatment.”

Massachusetts-based genetic profiling company Foundation Medicine, which was taken over by Swiss company Roche in 2018, is continuing to grow its own dataset on the treatment of patients with cancer. Similarly, Chicago-based Tempus has worked to sequence patient tumors and is mining medical records to look for outcomes.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office